Collectively, these findings show that TRIM65 decreased disease severity in multiple mouse models of NLRP3-dependent acute inflammatory diseases (LPS-induced systemic inflammation and MSU-induced peritonitis and gouty arthritis) via suppression of the NLRP3 inflammasome. This evidence concerns the gene NLRP3 and gout.